Skip to main content
Equibles

Squadron Capital Management LLC

Position in ZNTL — Zentalis Pharmaceuticals, Inc.

CIK 2050709 WESTMONT, IL
Back to ZNTL Full portfolio

Position in ZNTL

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$17,945,000
+$9,448,460 QoQ
Shares Held
3,700,000
+1.9% QoQ
Ownership
5.16%
of shares outstanding
% of Portfolio
6.14%
of 13F equity value
Holder Rank
#3
of 114 holders
Holding Since
Mar 2026
2 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in ZNTL Over Time

Shares Held

Position Value (USD)

Derivatives in ZNTL

reported options exposure · as of Jun 30, 2026
CallValue
$2,066,100
CallShares
426,000
PutValue
$0
PutShares
0

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

Squadron Capital Management LLC holds $280,459,987 across 30 Biotechnology names. ZNTL ranks #6 (6.4% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 RLMD
Relmada Therapeutics, Inc.
 7,350,000 $50,862,000
2 CCCC
C4 Therapeutics, Inc.
 7,200,000 $33,624,000
3 COGT
Cogent Biosciences, Inc.
 865,000 $33,475,500
4 KOD
Kodiak Sciences Inc.
 500,000 $19,480,000
5 RLAY
Relay Therapeutics, Inc.
 970,000 $18,148,700
6 ZNTL
Zentalis Pharmaceuticals, Inc.
This page 		3,700,000 $17,945,000
7 EWTX
Edgewise Therapeutics, Inc.
 290,000 $11,782,700
8 MAZE
Maze Therapeutics, Inc.
 335,000 $9,996,400

All Filings in ZNTL

Export CSV
4 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $17,945,000 3,700,000
2026-06-30 $2,066,100 426,000
2026-03-31 $8,496,540 3,631,000
2026-03-31 $936,000 400,000